自身免疫性肝炎患者血清细胞因子水平变化及其与治疗应答的关系研究*

doi:10.3969/j.issn.1672-5069.2024.06.014

摘要/Abstract

摘要： 目的分析自身免疫性肝炎(AIH)患者血清白细胞介素-6(IL-6)、IL-8和IL-10水平变化及其与治疗应答的关系。方法 2020年1 月～2023年12 月我科收治的60例AIH患者和同期体检的60例健康人,给予所有AIH患者醋酸泼尼松治疗6个月。采用化学发光法检测血清细胞因子水平。应用受试者工作特征曲线(ROC)分析血清细胞因子水平预测治疗应答的效能。结果治疗前,AIH组血清IL-6和IL-8水平分别为(7.5±2.5)pg/mL和(70.2±26.7)pg/mL,均显著高于健康人【分别为(4.8±1.4)pg/mL和(42.4±13.2)pg/mL,P＜0.05】,而血清IL-10水平为(4.2±1.1)pg/mL,显著低于健康人【(7.3±2.6)pg/mL,P＜0.05】;治疗后,AIH患者血清IL-6和IL-8水平显著降低,而血清IL-10水平显著升高(P＜0.05); 在治疗6个月末,本组AIH患者治疗应答率为56.7%,未应答或不完全应答率为43.3%;入组时,治疗应答组血清IL-6和IL-8水平分别为(4.9±1.4)pg/mL和(47.4±15.2)pg/mL,均显著低于未应答组【分别为(9.9±2.8)pg/mL和(108.3±28.7)pg/mL,P＜0.05】,而血清IL-10水平为(6.9±1.9)pg/mL,显著高于未应答组【(2.7±1.6)pg/mL,P＜0.05】;分别以IL-6≤4.8 pg/mL、IL-8≤48.0 pg/mL和IL-10＞6.8 pg/mL为截断点,ROC分析显示三个血清细胞因子联合预测治疗应答的曲线下面积(AUC)为0.816,其敏感度为100.0%,特异度为50.0%。结论 AIH患者血清IL-6和IL-8水平异常升高,而血清IL-10水平降低,它们可能参与了疾病的发生发展过程,并对治疗应答产生影响,值得深入研究。

关键词: 自身免疫性肝炎, 白细胞介素-6, 白细胞介素-8, 白细胞介素-10, 皮质激素, 治疗应答, 预测

Abstract: Objective The aim of this study was to investigate serum interleukin-6 (IL-6), IL-8 and IL-10 level changes and their impact on response to steroid therapy in patients with autoimmune hepatitis (AIH). Methods 60 patients with AIH and 60 healthy individuals were recruited in our hospital between January 2020 and December 2023, and all patients received prednisone treatment for six months. Serum IL-6, IL-8 and IL-10 levels were measured by chemiluminescence method. Performance for predicting response to therapy was analyzed by using receiver operating characteristic (ROC) curves. Results At admission, serum IL-6 and IL-8 levels in patients with AIH were (7.5±2.5)pg/mL and (70.2±26.7)pg/mL, both significantly higher than [(4.8±1.4)pg/mL and (42.4±13.2)pg/mL, respectively, P＜0.05], while serum IL-10 levels was (4.2±1.1)pg/mL, much lower than [(7.3±2.6)pg/mL, P＜0.05] in healthy individuals; by end of six month treatment, serum IL-6 and IL-8 levels obviously decreased and serum IL-10 level increased (P＜0.05) in patients with AIH; 56.7% of patients with AIH in our series responded, while 43.3% of them didn’t completely responded to steroid therapy; at presentation, serum IL-6 and IL-8 levels in responders were (4.9±1.4)pg/mL and (47.4±15.2)pg/mL, both significantly lower than [(9.9±2.8)pg/mL and (108.3±28.7)pg/mL, respectively, P＜0.05], while serum IL-10 level was (6.9±1.9)pg/mL, much higher than [(2.7±1.6)pg/mL, P＜0.05] in non-responders; ROC analysis showed that AUC was 0.816, with sensitivity of 100.0% and specificity of 50.0%, when serum IL-6, IL-8 and IL-10 (≤4.8 pg/mL, ≤48.0 pg/mL and ＞6.8 pg/mL as cut-off-value, respectively) combination in predicting response to steroid therapy. Conclusion Serum IL-6, IL-8 and IL-10 levels in patients with AIH change abnormally, which might be involved in pathogenesis of the disease, and impact response to immunosuppression therapy.

Key words: Autoimmune hepatitis, Interleukin-6, Interleukin-8, Interleukin-10, Steroid treatment, Response, Prediction

陈蓉蓉, 蒋黎黎, 曹利华. 自身免疫性肝炎患者血清细胞因子水平变化及其与治疗应答的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 852-855.

Chen Rongrong, Jiang Lili, Cao Lihua. Serum IL-6, IL-8 and IL-10 levels and their impact on response to steroid therapy in patients with autoimmune hepatitis[J]. Journal of Practical Hepatology, 2024, 27(6): 852-855.

参考文献

[1] Olivas I, Rodríguez-Tajes S, Londoño MC. Autoimmune hepatitis: Challenges and novelties. Med Clin (Barc), 2022,159(6):289-298.
[2] Sirbe C, Simu G, Szabo I,et al. Pathogenesis of autoimmune hepatitis-Cellular and molecular mechanisms. Int J Mol Sci, 2021,22(24):13578.
[3] 伍慧丽,时红波,段钟平. 淋巴细胞在自身免疫性肝炎发病机制中的作用. 中华肝脏病杂志,2022,30(3):335-339.
[4] Harrington C, Krishnan S, Mack CL,et al. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology, 2022,76(6):1862-1879.
[5] 张洁,梁平,李建波,等. 青蒿鳖甲汤加减治疗癌性发热疗效及对NF-κB p65蛋白、IL-6、IL-10、TNF-α的影响. 中华中医药学刊,2023,41(5):220-223.
[6] Alrabadi LS, Dutton A, Rabiee A,et al. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Rep, 2022,4(5):100450.
[7] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015年). 中华肝脏病杂志,2016,24(1):23-35.
[8] 窦婧,徐强,王转国,等. 血清IgG低水平和转氨酶正常的AIH患者临床和肝组织病理学特征分析. 实用肝脏病杂志,2023,26(2):222-225.
[9] 谭晓燕,苗琪,陈晓宇. 抗线粒体抗体阴性原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的临床病理分析. 中华肝脏病杂志,2019,27(5):376-380.
[10] Harrington C, Krishnan S, Mack CL, et al. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology, 2022,76(6):1862-1879.
[11] ZKaur S, Bansal Y, Kumar R, et al. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorg Med Chem, 2020,28(5):115327.
[12] hang Q, Luo Y, Zheng Q, et al. Itaconate attenuates autoimmune hepatitis via PI3K/AKT/mTOR pathway-mediated inhibition of dendritic cell maturation and autophagy. Heliyon, 2023,9(7):e17551.
[13] Gonzalez-Aparicio M, Alfaro C. Significance of the IL-8 pathway for immunotherapy. Hum Vaccin Immunother, 2020,16(10):2312-2317.
[14] 王海波,时详,王宇,等. IL-8和GRO-α与U-HBP评估ICU脓毒症患者预后的临床价值. 中华医院感染学杂志,2023,33(2):161-165.
[15] Alrabadi LS, Dutton A, Rabiee A, et al. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Rep, 2022,4(5):100450.
[16] Czaja AJ. Immune inhibitory properties and therapeutic prospects of transforming growth factor-beta and interleukin 10 in autoimmune hepatitis. Dig Dis Sci, 2022,67(4):1163-1186.
[17] Czaja AJ. Targeting the B cell activation system in autoimmune hepatitis. Aliment Pharmacol Ther, 2021,54(7):902-922.
[18] Temel EN, Akcam FZ, Caner V, et al. Relationship between IL-17, TNF-α, IL-10, IFN-γ, and IL-18 polymorphisms with the outcome of hepatitis B virus infection in the Turkish population. Rev Assoc Med Bras (1992), 2023,69(8): e20230355.
[19] Wang M, Hou Y, Meng SH, et al. Abnormal IL-10 levels were related to alanine aminotransferase abnormalities during postpartum in HBeAg positive women with chronic hepatitis B. Medicine (Baltimore), 2019,98(46):e17969.
[20] Pape S, Snijders RJALM, Gevers TJG, et al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol, 2022,76(4):841-849.

自身免疫性肝炎患者血清细胞因子水平变化及其与治疗应答的关系研究^*

Serum IL-6, IL-8 and IL-10 levels and their impact on response to steroid therapy in patients with autoimmune hepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈大同, 岳展伊, 张小蓬. 自身免疫性肝病患者SH2B3基因Rs3184504单核苷酸多态性分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 856-859.
[2]	高宇, 杨磊, 胡光明, 孙占虎, 周涛, 肖杰. 自身免疫性肝炎患者血清巨噬细胞迁移抑制因子和白细胞介素-21水平变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 866-869.
[3]	高怡, 沈小雪, 夏素芹, 张洁, 朱先兰. 自身免疫性肝炎和原发性胆汁性胆管炎患者血清胆汁酸成分变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2024, 27(5): 709-712.
[4]	蒋叶舟, 花霞, 陈国飞, 朱青蓝, 蔡明月. 自身免疫性肝炎患者血清瘦素、外周血调节性T细胞和Th17细胞水平变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 713-716.
[5]	朱家瑞, 葛绍锋, 叶桂云, 黄远茂. 自身免疫性肝炎患者外周血NLR和nCD64指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(5): 717-720.
[6]	王燕燕, 周桐桐, 卞兆连. 原发性胆汁性胆管炎和原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征患者临床与肝组织病理学特点分析^*[J]. 实用肝脏病杂志, 2024, 27(5): 721-724.
[7]	王秀娟, 朱贺, 张茹梦, 常文绘, 刘玉玉. 泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者不同减量方法的效果研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 729-732.
[8]	任浩, 熊清芳. 多种无创检测指标预测自身免疫性肝病患者肝硬化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(4): 535-538.
[9]	蒋瑶, 仲伟明, 周俏怡, 邵宁, 吕冰, 孙舒. 吗替麦考酚酯治疗难治性自身免疫性肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 539-542.
[10]	黄静, 王菁, 方亮, 周娟, 商惠民. 血清wnt5a和LC3-Ⅱ联合MELD评分预测慢加急性乙型肝炎肝衰竭患者短期预后价值探讨^*[J]. 实用肝脏病杂志, 2024, 27(4): 551-554.
[11]	邢世磊, 李之慧, 宁秀景. 乙型肝炎肝硬化并发自发性细菌性腹膜炎患者血清MCP-1、TNF-α和IL-10水平变化及其与病情复发的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 563-566.
[12]	陈从新, 陈曦, 王莉苹, 赵秋香, 刘颖, 周海洋. 糖皮质激素在肝病治疗中的应用[J]. 实用肝脏病杂志, 2024, 27(3): 321-323.
[13]	金伯旬, 张丽, 娜仁图雅, 齐丽艳, 边新渠, 刘海霞, 王鑫, 栗光明. 急性表现与非急性表现的自身免疫性肝炎患者临床和肝组织病理学特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 366-369.
[14]	刘恋, 吉飞跃, 陈诺儿. 自身免疫性肝炎患者外周血单个核细胞CD6及其配体激活的白细胞粘附分子水平变化临床价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 370-373.
[15]	徐秋萍, 黄彬, 陈敏, 余静. 泼尼松与泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者外周血MDSCs百分比、肝组织白细胞介素-35和血清CD38水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 374-377.